Choose Your Country or Region

Infliximab (anti-TNF-alpha)

Catalog No.A2019 Purity:97.9%

Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

Selleck's Infliximab (anti-TNF-alpha) has been cited by 4 publications

Purity & Quality Control

Batch: A201901 Purity: 97.9% Protein concentration: 5.00mg/ml Endotoxin Level: <1EU/mg

97.9

Choose Selective TNF-alpha Inhibitors

Name	Citation	TNF-α	Others
Necrostatin-1	261	+
QNZ (EVP4593)	138	++++	NF-κB
GSK2982772	4	++
GSK481	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Infliximab (anti-TNF-alpha) is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that consists of mouse heavy and light chain variable regions combined with human heavy and light chain constant regions. Infliximab neutralizes the biological activity of TNF-α by binding with high affinity to the soluble and transmembrane forms of TNF-α, and inhibits or prevents the effective binding of TNF-α with its receptors. MW=144.2 kDa.

Description

In Vitro
In vitro	Infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.^[1] Infliximab does not exacerbate production of inflammatory cytokines, and does not affect expression of TNFR, proliferation of ARPE-19, HTLV-1 proviral load, or apoptosis of ARPE-19. Infliximab does not exacerbate HTLV-1-related inflammation in the eye and represents an acceptable treatment option under HTLV-1 infectious conditions.^[3]
Cell Research:	Objective: Glucose uptake assay Cells: murine 3T3L1 cell line Concentrations: 10 ng/ml Incubation Time: 2 hr Method: For glucose uptake assay, 3T3L1 mature adipocytes are in vitro cultured for 2 hr at 37°C in humidified 5% CO₂ atmosphere, using 6-well cell-culture plates at a density of 30×10⁴ cells per well. Adipocytes are stimulated twice at zero and 60 minutes with 2 μM insulin. In the infliximab-treated group, adipocytes are stimulated with 10 ng/ml infliximab at the beginning of the 2-hr in vitro assay. Reference: https://pubmed.ncbi.nlm.nih.gov/30260514 Objective: Cell Counts Cells: ARPE-19 cells, MT-2 cells, Jurkat cells Concentrations: 10 μg/ml Incubation Time: 24 h, 48 h, 72 h Method: ARPE-19 cells (2 × 10⁴) are co-cultured with three times the number of MT2 or Jurkat cells with or without Infliximab. After 0, 24, 48, or 72 h of co-culture, we remove the supernatants, trypsinized ARPE-19, and count the number of ARPE-19 cells under light microscopy. Reference: https://pubmed.ncbi.nlm.nih.gov/31620105 Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

In Vitro

In vitro

Infliximab ameliorates TNF-alpha-induced insulin resistance in 3T3L1 adipocytes in vitro by restoring the insulin signalling pathway via PTP1B inhibition.^[1] Infliximab does not exacerbate production of inflammatory cytokines, and does not affect expression of TNFR, proliferation of ARPE-19, HTLV-1 proviral load, or apoptosis of ARPE-19. Infliximab does not exacerbate HTLV-1-related inflammation in the eye and represents an acceptable treatment option under HTLV-1 infectious conditions.^[3]

Cell Research:

Objective: Glucose uptake assay
Cells: murine 3T3L1 cell line
Concentrations: 10 ng/ml
Incubation Time: 2 hr
Method: For glucose uptake assay, 3T3L1 mature adipocytes are in vitro cultured for 2 hr at 37°C in humidified 5% CO₂ atmosphere, using 6-well cell-culture plates at a density of 30×10⁴ cells per well. Adipocytes are stimulated twice at zero and 60 minutes with 2 μM insulin. In the infliximab-treated group, adipocytes are stimulated with 10 ng/ml infliximab at the beginning of the 2-hr in vitro assay.
Reference: https://pubmed.ncbi.nlm.nih.gov/30260514

Objective: Cell Counts
Cells: ARPE-19 cells, MT-2 cells, Jurkat cells
Concentrations: 10 μg/ml
Incubation Time: 24 h, 48 h, 72 h
Method: ARPE-19 cells (2 × 10⁴) are co-cultured with three times the number of MT2 or Jurkat cells with or without Infliximab. After 0, 24, 48, or 72 h of co-culture, we remove the supernatants, trypsinized ARPE-19, and count the number of ARPE-19 cells under light microscopy.
Reference: https://pubmed.ncbi.nlm.nih.gov/31620105

Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

In Vivo
In vivo	A single injection of infliximab in diabetic TNF-α(+/+) mice leads to suppression of the increased serum TNF-α and amelioration of the electrophysiological and biochemical deficits for at least 4 wk. Moreover, the increased TNF-α mRNA expression in diabetic DRG is also attenuated by infliximab, suggesting infliximab's effects may involve the local suppression of TNF-α. Infliximab, an agent currently in clinical use, is effective in targeting TNF-α action and expression and amelioration of diabetic neuropathy in mice.^[2] Mice given increasing doses of infliximab produces increasing levels of ADAs. Blood samples from mice given injections of human TNF and infliximab contains infliximab-TNF complexes.^[4]
Animal Research	Objective: To evaluate the effect on diabetic neuropathy Animal Models: 8-week-old C57BL/6J (WT, TNF-α+/+) and TNF-α-deficient (TNFα−/−) mice of strain B6.129S6-Tnf^tm1Gkl/J in the C57BL/6 background Formulation: Saline Dosages: 10 μg/g Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/21810933 Objective: pharmacokinetic (PK) study Animal Models: 6–8 week-old female C57BL/6 mice Formulation: -- Dosages: 0.3075 μg/g, 0.384 μg/g, 0.769 μg/g, 1.538 μg/g, 6.15 μg/g, 30.75 μg/g, 246 μg/g Administration: i.p. Reference: https://pubmed.ncbi.nlm.nih.gov/31401142 Infliximab can apply to humanized mice, non-humanized mice (eg: C57BL/6 mice), peripheral blood and other related assays (Only for Reference)

References
[1] Lucia A Méndez-García, et al. Scand J Immunol. 2018 Nov;88(5):e12716. [2] Isamu Yamakawa, et al. Am J Physiol Endocrinol Metab. 2011 Nov;301(5):E844-52. [3] Minami Uchida, et al. Front Microbiol. 2019 Sep 18;10:2148. [4] Haggai Bar-Yoseph, et al. Gastroenterology. 2019 Nov;157(5):1338-1351.e8. + Expand

References

[4] Haggai Bar-Yoseph, et al. Gastroenterology. 2019 Nov;157(5):1338-1351.e8.

+ Expand

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	170277-31-3
Molecular Weight	150 kDa
Isotype	Chimeric IgG1
Source	Chimeric (mouse/human)
Purification	Protein G
Sterility	0.2 μM filtered
Formulation	PBS, pH 7.0 Contains no stabilizers or preservatives
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.